Canaccord lowered the firm's price target on Neuronetics (STIM) to $3 from $7 and keeps a Buy rating on the shares. The firm said Q4 results and guidance are in line, but the most important news from the Q4 print and earnings call was the announcement of the new CEO, Dan Reuvers, a second quarter that was operationally cash flow positive, and the collaboration with Compass Pathways (CMPS).
